EICHORCondition: Atopic Dermatitis · Sponsor: Amgen
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The co-primary objectives of the study are to: * Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). * Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema Area and Severity Index (EASI).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Research Solutions of Arizona, PC | Litchfield Park, Arizona, United States | — |
| Center for Dermatology and Plastic Surgery | Scottsdale, Arizona, United States | — |
| Clinical Trials Institute of Northwest Arkansas | Fayetteville, Arkansas, United States | — |
| Burke Pharmaceutical Research | Hot Springs, Arkansas, United States | — |
| Velocity Clinical Research Chula Vista | Chula Vista, California, United States | — |
| West Coast Research LLC | Dublin, California, United States | — |
| California Dermatology and Clinical Research Institute | Encinitas, California, United States | — |
| Center for Dermatology Clinical Research Inc | Fremont, California, United States | — |
| Velocity Clinical Research - San Diego | La Mesa, California, United States | — |
| Velocity Clinical Research - North Hollywood | North Hollywood, California, United States | — |
| Cura Clinical Research | Palmdale, California, United States | — |
| University of California at San Francisco, Dermatology Clinic at Mount Zion | San Francisco, California, United States | — |
+ 185 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05651711